Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19280968 | COMBINATION OF NON-VIABLE CELLS OF STREPTOCOCCUS PYOGENES AND IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND NON-MUSCLE INVASIVE BLADDER CANCER | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 19277384 | HERBAL ORAL COMPOSITIONS HAVING THE PROPERTIES FOR SUPPORTING AND ENHANCING MUSCULOSKELETAL HEALTH AND METHOD OF MANUFACTURING THE SAME | July 2025 | November 2025 | Allow | 4 | 1 | 0 | No | No |
| 19269552 | CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE | July 2025 | November 2025 | Allow | 4 | 0 | 1 | No | No |
| 19247982 | APPARATUS FOR TISSUE TRANSPORT AND PRESERVATION | June 2025 | March 2026 | Allow | 8 | 1 | 1 | No | No |
| 19064774 | COMPOSITION AND METHOD FOR INDUCING NATURAL CONCEPTION | February 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18645314 | METHODS OF TREATING BLEEDING IN A SUBJECT TREATED WITH AN ANTIPLATELET AGENT | April 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18641028 | COMPOSITION FOR RESPIRATORY DISEASES | April 2024 | January 2026 | Allow | 21 | 2 | 1 | Yes | No |
| 18626055 | GENETICALLY MODIFIED ZYMOMONAS MOBILIS TO UTILIZE INORGANIC N SOURCE, METHODS AND USES THEREOF | April 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18605547 | NANOBANDAGE SOLUTION WITH FAIDHERBIA ALBIDA NANOPARTICLES AND NATURAL AND SYNTHETIC POLYMERS | March 2024 | November 2024 | Allow | 8 | 1 | 1 | No | No |
| 18434921 | GINSENOSIDE-CONTAINING COMPOSITION, DAILY-USE CHEMICAL AND USE THEREOF | February 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18411067 | USE OF RADIX ACTINIDIAE CHINENSIS AND EXTRACT THEREOF IN PREPARATION OF MEDICINE FOR TREATING ULCERATIVE COLITIS | January 2024 | January 2026 | Allow | 24 | 1 | 0 | No | No |
| 18410115 | De-constipation Method | January 2024 | August 2024 | Allow | 7 | 2 | 0 | No | No |
| 18407894 | ENU PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN | January 2024 | December 2024 | Allow | 11 | 1 | 1 | No | No |
| 18544256 | METHOD FOR INHIBITING FUNGAL GROWTH USING PYROPIA YEZOENSIS | December 2023 | September 2024 | Allow | 9 | 1 | 1 | No | No |
| 18514982 | Standardized psychoactive alkaloid extract composition | November 2023 | May 2024 | Allow | 6 | 1 | 1 | No | No |
| 18492378 | METHODS AND COMPOSITIONS FOR BIOPRESERVATION | October 2023 | January 2026 | Allow | 27 | 0 | 0 | Yes | No |
| 18286563 | METHOD AND DEVICE FOR ULTRA-RAPID CRYO-FIXATION OF A SAMPLE FOR MICROSCOPIC STUDIES | October 2023 | January 2026 | Allow | 27 | 0 | 0 | Yes | No |
| 18472708 | Biological Prosthesis and Methods of Production and Use | September 2023 | January 2026 | Allow | 28 | 1 | 0 | No | No |
| 18238478 | Transmucosal dephosphorylated psychoactive alkaloid composition and preparation thereof | August 2023 | November 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18234588 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | August 2023 | December 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18226395 | KRILL OIL COMPOSITION ENRICHED IN LPC-DHA AND LPC-EPA | July 2023 | May 2025 | Allow | 22 | 0 | 0 | No | No |
| 18225003 | CHLOROGENIC ACID COMPOSITION FOR PROMOTING A HEALTHY BODY WEIGHT | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18273655 | METHODS FOR MANUFACTURE OF NEURONAL PRECURSORS | July 2023 | February 2026 | Allow | 30 | 0 | 0 | Yes | No |
| 18220928 | Translucent, Dehydrated Placental Tissue and Methods of Producing and Using the Same | July 2023 | June 2025 | Allow | 24 | 0 | 0 | No | No |
| 18344457 | INSECTICIDAL PROTEINS FROM PLANTS AND METHODS FOR THEIR USE | June 2023 | December 2025 | Allow | 29 | 2 | 2 | Yes | No |
| 18337614 | POWDER SOLID COMPOSITIONS, PROCESS FOR THEIR PREPARATION, FORMULATIONS AND USE THEREOF | June 2023 | June 2025 | Allow | 24 | 0 | 0 | No | No |
| 18206355 | FORMULATION FOR MANAGEMENT OF POST-ORAL SURGICAL RECOVERY AND MAINTENANCE OF ORAL HEALTH | June 2023 | September 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 18206349 | ORAL RINSE FOR MANAGEMENT OF POST-ORAL SURGICAL RECOVERY AND MAINTENANCE OF ORAL HEALTH | June 2023 | June 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18199536 | COMPOSITIONS, METHODS, AND KITS FOR CLEANSING AND MOISTURIZING | May 2023 | May 2025 | Allow | 24 | 0 | 0 | No | No |
| 18253079 | PRECISION OXYGEN FLOW CONTROL FOR ORGAN PERFUSION SYSTEMS | May 2023 | October 2025 | Allow | 29 | 0 | 0 | No | No |
| 18318548 | THROMBOSOMES AS AN ANTIPLATELET AGENT REVERSAL AGENT | May 2023 | June 2025 | Allow | 25 | 0 | 0 | No | No |
| 18037019 | BIOREACTOR, APPARATUS AND PROCESS FOR IN VITRO CULTURE OF REPRODUCTIVE TISSUES, AND THE LIKE | May 2023 | January 2026 | Allow | 32 | 1 | 0 | No | No |
| 18143316 | ACELLULAR SOFT TISSUE-DERIVED MATRICES AND METHODS FOR USING SAME | May 2023 | March 2025 | Allow | 23 | 0 | 0 | No | No |
| 18306084 | APPARATUS FOR TISSUE TRANSPORT AND PRESERVATION | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18121280 | BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE | March 2023 | May 2024 | Allow | 14 | 0 | 0 | No | No |
| 17754945 | PHARMACEUTICAL COMPOSITION BASED ON PLANT EXTRACTS FOR THE TREATMENT OF FIBROMYALGIA, RHEUMATOID ARTHRITIS, LUPUS AND OTHER AUTOIMMUNE DISEASES | March 2023 | January 2026 | Allow | 45 | 2 | 0 | No | No |
| 18117415 | DIETARY SUPPLEMENT | March 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18112783 | IMMUNOLOGICALLY COMPATIBLE CELLS, TISSUES, ORGANS, AND METHODS FOR TRANSPLANTATION FOR SILENCING, HUMANIZATION, AND PERSONALIZATION WITH MINIMIZED COLLATERAL GENOMIC DISRUPTIONS | February 2023 | October 2025 | Allow | 32 | 0 | 0 | No | No |
| 18107348 | COMPOSITIONS IN SUPPORT OF HEALTH AND MENTAL ACCUITY | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18097822 | Blood Plasma Product | January 2023 | September 2024 | Allow | 20 | 2 | 1 | No | No |
| 18002773 | ORGAN PRESERVATION AND/OR PERFUSION SOLUTION | December 2022 | January 2026 | Allow | 37 | 0 | 1 | No | No |
| 18067681 | COMPOSITION FOR ENHANCED ABSORPTION OF SUPPLEMENTS | December 2022 | December 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17928889 | COMPOSITION FOR CRYOPROTECTION INCLUDING DNA NANOSTRUCTURE, AND METHOD FOR USING SAME | November 2022 | September 2025 | Allow | 34 | 0 | 0 | No | No |
| 18000374 | Valve Material With Combined Anti-Clotting And Anti-Calcification Properties And Preparation Method Therefor | November 2022 | December 2025 | Allow | 36 | 0 | 0 | No | No |
| 17993456 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | November 2022 | April 2025 | Allow | 29 | 1 | 0 | No | No |
| 17999582 | ENCAPSULATED RNA REPLICONS AND METHODS OF USE | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17990522 | COMPOSITIONS COMPRISING NANOPARTICLES, METHOD OF MAKING AND USES THEREOF | November 2022 | March 2024 | Allow | 16 | 1 | 2 | No | No |
| 17990276 | METHODS FOR COLLECTING, PROCESSING AND TRANSPORTING TISSUE GRAFTS | November 2022 | June 2024 | Allow | 19 | 1 | 0 | No | No |
| 17990156 | SKIN SENSITIZER DELIVERY SYSTEM | November 2022 | March 2026 | Abandon | 40 | 2 | 0 | No | No |
| 17989513 | COSMETIC COMPOSITIONS | November 2022 | March 2024 | Allow | 16 | 0 | 0 | No | No |
| 17987404 | PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES AND METHODS OF STORING AND TRANSPORT | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 18055125 | METHOD AND SYSTEM FOR EX-SITU NORMOTHERMIC HEART PERFUSION | November 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 18047499 | TRADITIONAL CHINESE HERBAL COMPOSITION FOR TREATING PULMONARY NODULE, PREPARATION METHOD THEREOF, AND HONEYED PILL | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17916359 | COMPOSITION FOR PROTECTING ISLET TRANSPLANTATION | September 2022 | March 2026 | Allow | 42 | 2 | 0 | Yes | No |
| 17954091 | Blood Plasma Fractions for Use in Liver Regeneration | September 2022 | March 2024 | Allow | 18 | 0 | 0 | No | No |
| 17952167 | COMPOSITION FOR THE TREATMENT OF URINARY TRACT INFECTIONS | September 2022 | January 2026 | Allow | 40 | 2 | 0 | No | No |
| 17949178 | VEGETABLE POWDERS, METHODS FOR MANUFACTURING VEGETABLE POWDERS, AND KITS THEREOF | September 2022 | September 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17946661 | Skin Care Compositions and Methods of Use Thereof | September 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17946843 | BIOLOGIC PRESERVING COMPOSITION AND METHODS OF USE | September 2022 | October 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17882693 | SILICONE-BASED MEMBRANE SURFACE CHEMISTRY AND TOPOGRAPHY CONTROL FOR MAKING SELF-ASSEMBLED CELL SHEETS WITH CELL ALIGNMENT AND POSITIONING | August 2022 | March 2023 | Allow | 7 | 1 | 0 | No | No |
| 17817759 | SKIN CARE FORMULATIONS | August 2022 | October 2023 | Allow | 14 | 2 | 1 | No | No |
| 17815548 | Pharmaceutical Composition Based on Plant Raw Materials: #2.1 | July 2022 | August 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17807621 | ADIPOSE TISSUE PARTICLE PROCESSING, TRANSFER AND STORAGE SYSTEM | June 2022 | February 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17840482 | TRANSMUCOSAL PSYCHOACTIVE ALKALOID COMPOSITION AND PREPARATION THEREOF | June 2022 | August 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17836837 | SOLUTION BASED POST-PROCESSING METHODS FOR MYCOLOGICAL BIOPOLYMER MATERIAL AND MYCOLOGICAL PRODUCT MADE THEREBY | June 2022 | August 2025 | Allow | 39 | 1 | 1 | No | No |
| 17835407 | COMPOSITIONS AND METHODS OF PRODUCING DE-FLAVORED PEPPERCORN | June 2022 | October 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17826188 | THE TOPICAL COMPOSITION WITH ACTIVE COMPOUNDS FROM CANNABIS SATIVA AND CALENDULA OFFICINALIS FOR REDUCTION OF SKIN LESIONS | May 2022 | July 2023 | Allow | 13 | 0 | 0 | No | No |
| 17827113 | COSMETIC FORMULATION | May 2022 | October 2024 | Allow | 29 | 1 | 0 | No | No |
| 17824655 | COMPOSITION FOR PREVENTING AGE-RELATED METABOLIC AND TISSUE DEGENERATIVE CHANGES | May 2022 | August 2023 | Allow | 15 | 1 | 1 | No | No |
| 17743362 | LIQUID COMPOSITION FOR USE IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX | May 2022 | February 2023 | Allow | 9 | 0 | 0 | No | No |
| 17739241 | Herbal composition for metabolic syndromes and method of treatment thereof | May 2022 | January 2025 | Abandon | 32 | 4 | 1 | Yes | No |
| 17737680 | CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE | May 2022 | March 2023 | Allow | 11 | 0 | 0 | No | No |
| 17727679 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | April 2022 | November 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17771401 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | April 2022 | June 2025 | Allow | 38 | 0 | 1 | No | No |
| 17711075 | COMPOSITIONS, METHODS, AND KITS FOR CLEANSING AND MOISTURIZING | April 2022 | February 2023 | Allow | 11 | 0 | 0 | No | No |
| 17697321 | DIETARY SUPPLEMENT | March 2022 | January 2023 | Allow | 10 | 0 | 0 | No | No |
| 17697333 | DIETARY SUPPLEMENT | March 2022 | January 2023 | Allow | 10 | 0 | 0 | No | No |
| 17682190 | COMPOSITIONS AND METHODS USEFUL IN TREATMENT OF LOWER URINARY TRACT SYMPTOMS, BENIGN PROSTATIC HYPERPLASIA, ERECTILE DYSFUNCTION, AND OTHER DISEASES OR SYMPTOMS | February 2022 | November 2024 | Allow | 33 | 1 | 1 | No | No |
| 17591588 | DIETARY SUPPLEMENT | February 2022 | January 2023 | Allow | 12 | 0 | 0 | No | No |
| 17591582 | DIETARY SUPPLEMENT | February 2022 | January 2023 | Allow | 12 | 0 | 0 | No | No |
| 17648845 | FORMULATION AND DELIVERY SYSTEMS FOR HERBAL COMPOSITIONS FOR THE TREATMENT OF CANKER SORES (RECURRENT APHTHOUS STOMATITIS) AND RELATED CONDITIONS | January 2022 | January 2024 | Allow | 23 | 1 | 1 | No | No |
| 17564459 | COMPOSITION CONTAINING NATURAL EXTRACTS FOR ENHANCEMENT OF INNATE IMMUNITY OR ANTIVIRAL USE AGAINST INFLUENZA VIRUS OR CORONA VIRUS | December 2021 | December 2024 | Abandon | 36 | 3 | 2 | Yes | No |
| 17559284 | HUMAN MILK PRODUCTS USEFUL IN PRE- AND POST-OPERATIVE CARE | December 2021 | February 2024 | Allow | 25 | 1 | 0 | No | No |
| 17536841 | ACELLULAR SOFT TISSUE-DERIVED MATRICES AND METHODS FOR USING SAME | November 2021 | January 2023 | Allow | 14 | 0 | 0 | No | No |
| 17530951 | TOPICAL MOSQUITO CONTROL PRODUCT | November 2021 | February 2026 | Abandon | 51 | 1 | 0 | No | No |
| 17529213 | TRADITIONAL CHINESE MEDICINE COMPOUND COMPOSITION WITH IMMUNE BIDIRECTIONAL REGULATION EFFECT AND PREPARATION METHOD AND APPLICATIONS THEREOF | November 2021 | February 2026 | Allow | 51 | 3 | 1 | No | No |
| 17516186 | METHODS AND MATERIALS FOR TREATING DIABETES OR LIVER STEATOSIS | November 2021 | December 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17508904 | Formulations and Methods for Contemporaneous Stabilization of Active Proteins During Spray Drying and Storage | October 2021 | March 2023 | Allow | 17 | 0 | 0 | No | No |
| 17506823 | PRESERVATION SOLUTIONS | October 2021 | June 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17486638 | Translucent, Dehydrated Placental Tissue and Methods of Producing and Using the Same | September 2021 | January 2023 | Allow | 15 | 0 | 0 | No | No |
| 17486642 | Translucent, Dehydrated Placental Tissue and Methods of Producing and Using the Same | September 2021 | January 2023 | Allow | 15 | 0 | 0 | No | No |
| 17484389 | COMPOSITIONS WITH AGENTS FOR MITIGATING METHANOGENESIS IN ANIMALS AND RELATED METHODS | September 2021 | April 2024 | Allow | 31 | 1 | 1 | No | No |
| 17435650 | PLANT-DERIVED EXOSOME-LIKE NANOPARTICLES INHIBIT BACTERIAL PATHOGENICITY | September 2021 | September 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17461486 | Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline | August 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17403360 | METHOD OF REMOVING FLOATATION LIQUID | August 2021 | January 2024 | Allow | 29 | 1 | 0 | No | No |
| 17395249 | Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions | August 2021 | February 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17389203 | ORAL COMPOSITIONS FOR BLADDER REGULATION AND USES THEREOF | July 2021 | August 2022 | Allow | 13 | 0 | 0 | No | No |
| 17387158 | NEUROPROTECTION AND NEUROREGENERATION BY PTEROSTILBENE AND COMPOSITIONS THEREOF | July 2021 | October 2022 | Allow | 14 | 0 | 0 | No | No |
| 17423066 | ANTI INFLAMMATORY COMPOSITION | July 2021 | September 2024 | Allow | 39 | 1 | 1 | No | No |
| 17367308 | PLANT EXTRACT OBTAINED FROM MORUS PLANT LEAVES WHICH HAS AN IC50 VALUE TO INHIBIT a-GLUCOSIDASE I AT A CONCENTRATION OF LESS THAN 90 uG/ML, COMPOSITIONS CONTAINING SAME, METHOD OF EXTRACTION AND USES THEREOF | July 2021 | August 2023 | Allow | 25 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOSAR, AARON J.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KOSAR, AARON J works in Art Unit 1655 and has examined 552 patent applications in our dataset. With an allowance rate of 76.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 33 months.
Examiner KOSAR, AARON J's allowance rate of 76.8% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KOSAR, AARON J receive 1.52 office actions before reaching final disposition. This places the examiner in the 27% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KOSAR, AARON J is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +18.3% benefit to allowance rate for applications examined by KOSAR, AARON J. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.8% of applications are subsequently allowed. This success rate is in the 53% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 38.2% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 64.7% of appeals filed. This is in the 45% percentile among all examiners. Of these withdrawals, 36.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 57.4% are granted (fully or in part). This grant rate is in the 60% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.